[1]
|
Suppiah R, Robson JC, Grayson PC, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis[J]. Arthritis Rheumatol, 2022, 74: 400-406. doi: 10.1002/art.41983 |
[2]
|
Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis[J]. J Am Soc Nephrol, 2010, 21: 1628-1636. doi: 10.1681/ASN.2010050477 |
[3]
|
Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases[J]. Kidney Int, 2021, 100: 753-779. doi: 10.1016/j.kint.2021.05.015 |
[4]
|
Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis[J]. N Engl J Med, 2010, 363: 221-232. doi: 10.1056/NEJMoa0909905 |
[5]
|
Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis (RITUXVAS)[J]. N Engl J Med, 2010, 363: 211-220. doi: 10.1056/NEJMoa0909169 |
[6]
|
Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis[J]. N Engl J Med, 2014, 371: 1771-1780. doi: 10.1056/NEJMoa1404231 |
[7]
|
Sanderson J, Ansari A, Marinaki T, et al. Thiopurine methyltransferase: should it be measured before commencing thiopur-ine drug therapy[J]. Ann Clin Biochem, 2004, 41: 294-302. doi: 10.1258/0004563041201455 |
[8]
|
Tieu J, Smith R, Basu N. et al. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines[J]. Rheumatology (Oxford), 2020, 59: e24-e32. doi: 10.1093/rheumatology/kez640 |
[9]
|
Goel R, Morgan M, Chanouzas D, et al. Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis[J]. Rheumatol Adv Pract, 2021, 5: rkab039. doi: 10.1093/rap/rkab039 |
[10]
|
Moiseev SV, Bulanov NM, Zykova AS, et al. Rituximab in ANCA-associated vasculitis: fewer infusions or ultra low-dose maintenance therapy[J]. Ann Rheum Dis, 2019, 78: e99. doi: 10.1136/annrheumdis-2018-213873 |
[11]
|
Schoergenhofer C, Schwameis M, Firbas C, et al. Single, very low rituximab doses in healthy volunteers—a pilot and a randomized trial: implications for dosing and biosimilarity testing[J]. Sci Rep, 2018, 9: 124. |
[12]
|
Charles P, Terrier B, Perrodeau E, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase Ⅲ trial (MAINRITSAN2)[J]. Ann Rheum Dis, 2018, 77: 1143-1149. doi: 10.1136/annrheumdis-2017-212878 |
[13]
|
Van Dam LS, Oskam JM, Kamerling SWA, et al. Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients[J]. Front Immunol, 2020, 11: 566732. doi: 10.3389/fimmu.2020.566732 |
[14]
|
Charles P, Perrodeau É, Samson M, et al. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial[J]. Ann Intern Med, 2020, 173: 179-187. doi: 10.7326/M19-3827 |
[15]
|
Merkel PA, Niles JL, Mertz LE, et al. Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis and in Microscopic Polyangiitis[J]. Arthritis Care Res (Hoboken), 2021, 73: 1372-1378. doi: 10.1002/acr.24332 |
[16]
|
Jyssum I, Kared H, Tran TT, et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study[J]. Lancet Rheumatol, 2022, 4: e177-e187. doi: 10.1016/S2665-9913(21)00394-5 |
[17]
|
Andersen KM, Bates BA, Rashidi ES, et al. Long-term use of immunosuppressive medicines and in-hospital COVID-10 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative[J]. Lancet Rheumatol, 2022, 4: e33-e41. doi: 10.1016/S2665-9913(21)00325-8 |